Onclast en es it fr

Onclast Brand names, Onclast Analogs

Onclast Brand Names Mixture

  • No information avaliable

Onclast Chemical_Formula


Onclast RX_link


Onclast fda sheet

Onclast FDA

Onclast msds (material safety sheet)

Onclast MSDS

Onclast Synthesis Reference

M. I. Kabachnik et al., Bull. Acad. Sci. USSR,.27, 374 (1978)

Onclast Molecular Weight

249.096 g/mol

Onclast Melting Point

233 - 235 oC

Onclast H2O Solubility


Onclast State


Onclast LogP


Onclast Dosage Forms

Tablets (6.53, 13.05, 45.68, 52.21 or 91.37 mg of alendronate monosodium salt trihydrate)

Onclast Indication

For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.

Onclast Pharmacology

Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women.

Onclast Absorption

Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast.

Onclast side effects and Toxicity

Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis."

Onclast Patient Information

Onclast Organisms Affected

Humans and other mammals